** Shares of eye drug developer Alimera Sciences fall 16.67% to $4.61
** Co files lawsuit to compel ANI Pharmaceuticals to close merger transaction
** The lawsuit asks the court to require ANI to comply with its obligations to complete the transaction as contemplated by the agreement
** The companies announced their agreement in June, valuing ALIM at about $381 mln in upfront consideration
** ALIM up ~6% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.